Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Pierre Fabre prepares agents with antidopaminergic/antiserotonergic effects

May 5, 1997

Preclinical results for N-3389 in emesis

May 5, 1997

Agents specific for dopamine D3 receptors described by Neurogen

May 5, 1997

Delta-opioid receptor ligands reported by SmithKline Beecham

May 5, 1997

CoCensys and Novartis end stroke compound collaboration

May 2, 1997

Neurobiological Technologies initiates second phase II memantine trial

May 2, 1997

Modafinil for sleep apnea-hypopnea syndrome

May 2, 1997

Positive clinical results for pramipexole in schizophrenia

May 2, 1997

Antioxidants reported by Hoechst Marion Roussel

May 2, 1997

Nippon Kayaku reports neuritogenic effects for known compound

May 2, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...